Other OTC - Delayed Quote USD

Better Therapeutics, Inc. (BTTX)

0.0100 +0.0010 (+11.11%)
At close: April 26 at 3:53 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman 260k -- 1968
Mr. Frank L. Karbe CEO, Interim CFO, President & Director 533.37k -- 1968
Dr. Mark A. Berman M.D. Chief Medical Officer 573.75k -- 1976
Ms. Kristin Wynholds Chief Product Officer 519.07k -- 1973
Mr. Andres Camacho Senior VP of Technology & Head of Engineering -- -- --
Ms. Angela Willis Senior Vice President of Market Access -- -- --
Ms. Jessica Meng Chief Commercial Officer -- -- --
Leslie Miller Controller -- -- --

Better Therapeutics, Inc.

548 Market Street
Suite 49404
San Francisco, CA 94104
United States
415 887 2311 https://www.bettertx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
54

Description

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Corporate Governance

Better Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 29, 2024 - May 04, 2024
Better Therapeutics, Inc. Earnings Call

Related Tickers

CLNN Clene Inc.
0.3399
-1.90%
 
BLPH Bellerophon Therapeutics, Inc.
0.0554
+0.73%
 
ZVSA ZyVersa Therapeutics, Inc.
4.9900
-16.83%
 
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
SNTI Senti Biosciences, Inc.
0.2900
+4.05%
 
BCEL Atreca, Inc.
0.0800
-6.43%
 
CLDI Calidi Biotherapeutics, Inc.
0.1607
+0.44%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.6375
+1.21%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%